Tilray Brands, Inc. Common Stock (TLRY)
Tilray Brands, Inc. is a global leader in the production and distribution of medical cannabis, adult-use cannabis, and wellness products. Founded in 2013, the company operates through various subsidiaries and brands, offering a range of cannabis products, including cannabis flowers, oils, and edibles, to both medical and recreational markets worldwide. Tilray emphasizes research, quality, and innovation within the rapidly evolving cannabis industry.
Company News
A video posted on Truth Social by the Commonwealth Project suggests potential federal marijuana legalization, with implications for Medicare coverage of medical marijuana and significant stock market reactions in cannabis companies.
Tilray's stock surged over 60% on September 29 following political commentary about CBD's medical potential, triggering a short squeeze and drawing attention to the company's improving financial fundamentals.
Tilray Medical announced the expansion of its Craft Cannabis portfolio in Germany, adding five new cannabis flower products manufactured in its EU-GMP-certified facility in Neumünster, demonstrating commitment to providing high-quality medical cannabis options for patients and healthcare professionals.
OrganiGram's stock surged 15% after former President Trump's social media post suggesting potential health benefits of cannabis and a possible shift in federal drug policy, boosting optimism in the cannabis industry.
Tilray Brands reported Q4 2024 revenue of $229.88 million, up 24.8% year-over-year, and EPS of -$0.04 compared to $0.00 in the prior year. The company's performance was mixed compared to analyst estimates, with revenue beating expectations but EPS missing.
